Claims
- 1. An indolinone compound of formula I or II, ##STR187## or the pharmaceutically acceptable salt thereof where
- (a) R.sub.1 is selected from the group consisting of,
- (i) alkyl that is optionally substituted with a monocyclic or bicyclic five, six, eight, nine, or ten membered heterocyclic ring, where the ring is optionally substituted with one or more halogen, or trihalomethyl substituents;
- (ii) five, six, eight, nine, or ten membered monocyclic or bicyclic heterocyclic ring, where the ring is optionally substituted with one or more halogen or trihalomethyl substituents;
- (iii) ketone of formula --CO--R.sub.12, where R.sub.12 is selected from the group consisting of hydrogen, alkyl, or a five or six membered heterocyclic ring;
- (iv) a carboxylic acid of formula -(R.sub.13).sub.n --COOH or ester of formula -(R.sub.14).sub.m --COO--R.sub.15, where R.sub.13, R.sub.14, and R.sub.15 and are independently selected from the group consisting of alkyl or a five or six membered heterocyclic ring and n and m are independently 0 or 1;
- (v) a sulfone of formula --(SO.sub.2)--R.sub.16, where R.sub.16 is selected from the group consisting of alkyl or a five or six membered heterocyclic ring, where the ring is optionally substituted with an alkyl moiety;
- (vi) -(R.sub.17).sub.n -(indole-1-yl) or -(R.sub.18).sub.m --CHOH--(R.sub.19).sub.p -(indole-1-yl), where the indole moiety is optionally substituted with an aldehyde and R.sub.17, R.sub.18, and R.sub.19 are alkyl and n, m, and p are independently 0 or 1;
- (vii) taken together with a 2' substituent of the indole ring forms a tricyclic moiety, where each ring in the tricyclic moiety is a five or six membered heterocyclic ring; and
- (viii) hydrogen;
- (b) R.sub.2, R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, and R.sub.6' are selected from the group consisting of,
- (i) hydrogen;
- (ii) alkyl that is optionally substituted with a monocyclic or bicyclic five, six, eight, nine, or ten membered heterocyclic ring, where the ring is optionally substituted with one or more halogen, or trihalomethyl substituents;
- (iii) five, six, eight, nine, or ten membered monocyclic or bicyclic heterocyclic ring, where the ring is optionally substituted with one or more halogen or trihalomethyl substituents;
- (iv) ketone of formula --CO--R.sub.20, where R.sub.20 is selected from the group consisting of hydrogen, alkyl, or a five or six membered heterocyclic ring;
- (v) a carboxylic acid of formula -(R.sub.21).sub.n --COOH or ester of formula -(R.sub.22)--COO--R.sub.23, where R.sub.21, R.sub.22, and R.sub.23 and are independently selected from the group consisting of alkyl or a five or six membered heterocyclic ring and m and n are independently 0 or 1;
- (vi) halogen;
- (vii) an alcohol of formula (R.sub.24).sub.m --OH or an ether of formula -(R.sub.24).sub.n --O--R.sub.25, where R.sub.24 and R.sub.25 are independently selected from the group consisting of alkyl and a five or six membered heterocyclic ring and m and n are independently 0 or 1;
- (viii) --NR.sub.26 R.sub.27, where R.sub.26 and R.sub.27 are independently selected from the group consisting of hydrogen, oxygen, alkyl, and a five or six membered heterocyclic ring;
- (ix) --NHCOR.sub.28, where R.sub.28 is selected from the group consisting of hydroxyl, alkyl, and a five or six membered heterocyclic ring, where the ring is optionally substituted with alkyl, halogen, carboxylate, or ester;
- (x) --SO.sub.2 NR.sub.29 R.sub.30, where R.sub.29 and R.sub.30 are selected from the group consisting of hydrogen, oxygen, alkyl, and a five or six membered heterocyclic ring;
- (xi) any two of R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, or R.sub.6' taken together form a bicyclic or tricyclic heterocyclic moiety fused to the six membered ring of the indole, where each ring in the multicyclic moiety is a five or six membered heterocyclic ring;
- (c) R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are independently selected from the group consisting of,
- (i) hydrogen;
- (ii) alkyl that is optionally substituted with a monocyclic or bicyclic five, six, eight, nine, or ten membered heterocyclic ring, where the ring is optionally substituted with one or more halogen, or trihalomethyl substituents;
- (iii) five, six, eight, nine, or ten membered monocyclic or bicyclic heterocyclic ring, where the ring is optionally substituted with one or more halogen or trihalomethyl substituents;
- (iv) ketone of formula --CO--R.sub.31, where R.sub.31 is selected from the group consisting of hydrogen, alkyl, or a five or six membered heterocyclic ring;
- (v) a carboxylic acid of formula -(R.sub.32).sub.n --COOH or ester of formula -(R.sub.33).sub.m --COO--R.sub.34, where R.sub.32, R.sub.33, and R.sub.34 and are independently selected from the group consisting of alkyl or a five or six membered heterocyclic ring and n and m are independently 0 or 1;
- (vi) halogen;
- (vii) an alcohol of formula (R.sub.35).sub.m --OH or an ether of formula -(R.sub.35).sub.n --O--R.sub.36, where R.sub.35 and R.sub.36 are independently chosen from the group consisting of alkyl or a five or six membered heterocyclic ring and m and n are independently 0 or 1;
- (viii) --NR.sub.37 R.sub.38, where R.sub.37 and R.sub.38 are independently selected from the group consisting of hydrogen, oxygen, alkyl, and a five or six membered heterocyclic ring;
- (ix) --NHCOR.sub.39, where R.sub.39 is selected from the group consisting of hydroxyl, alkyl, and a five or six membered heterocyclic ring, where the ring is optionally substituted with alkyl, halogen, carboxylate, or ester;
- (x) --SO.sub.2 NR.sub.40 R.sub.41, where R.sub.40 and R.sub.41 are selected from the group consisting of hydrogen, oxygen, alkyl, and a five or six membered heterocyclic ring;
- (xi) any two of R.sub.7, R.sub.8, R.sub.9, or R.sub.10 taken together form a bicyclic or tricyclic heterocyclic moiety fused to the six membered ring of the indole, where each ring in the multicyclic moiety is a five or six membered heterocyclic ring; and
- (d) R.sub.11 is hydrogen or alkyl or a pharmaceutically acceptable salt thereof.
- 2. The compound or salt of claim 1, wherein R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, and R.sub.6' are hydrogen.
- 3. The compound or salt of claim 1, wherein R.sub.1 and R.sub.11 are hydrogen.
- 4. The compound or salt of claim 1, wherein R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are independently selected from the group consisting of lower alkyl, halogen and NH.sub.2.
- 5. The compound or salt of formula I of claim 1, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, R.sub.6', R.sub.7, R.sub.8, R.sub.9, R.sub.10, and R.sub.11 are hydrogen.
- 6. The compound or salt of formula I of claim 1, where R.sub.8 is bromine, chlorine, or NH.sub.2 and R.sub.1, R.sub.2, R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, R.sub.6', R.sub.7, R.sub.9, R.sub.10, and R.sub.11 are hydrogen.
- 7. The compound or salt of formula I of claim 1, where R.sub.7 is methyl and R.sub.1, R.sub.2, R.sub.3, R.sub.3', R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, R.sub.6', R.sub.7, R.sub.9, R.sub.10, and R.sub.11 are hydrogen.
- 8. A pharmaceutical composition comprising a compound of any one of claims 1-7 and a physiologically acceptable carrier or diluent.
- 9. A method of treating an abnormal condition in an organism, where the abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a protein kinase and a natural binding partner, where the method comprises the following steps:
- (a) administering a compound of any one of claims 1-7 to an organism; and
- (b) promoting or disrupting the abnormal interaction.
- 10. The method of claim 9, where the organism is a mammal.
- 11. The method of claim 9, where the protein kinase is a FLK protein kinase.
- 12. The method of claim 9, where the protein kinase is a platelet derived growth factor receptor protein kinase.
- 13. A method of modulating the catalytic activity of a protein kinase with an indolinone compound or salt of claim 1.
- 14. The method of claim 13, where the protein kinase is a FLK protein kinase.
- 15. The method of claim 13, where the protein kinase is a platelet derived growth factor receptor protein kinase.
RELATED APPLICATIONS
This application relates to U.S. patent applications Ser. No. 60/031,586, filed Dec. 5, 1996, entitled "FLK Specific Indolinone Compounds and Related Products and Methods for the Treatment of Disease" by McMahon et al.; Ser. No. 60/045,566, filed May 5, 1997, entitled "FLK Specific Indolinone Compounds and Related Products and Methods for the Treatment of Disease" by McMahon et al.; Ser. No. 60/032,546, filed Dec. 5, 1996, entitled "HYDROSOLUBLE INDOLINE TYROSINE KINASE INHIBITORS" by McMahon et al.; Ser. No. 60/045,715, filed Dec. 5, 1996, entitled "SUBSTITUTED 3-[(TETRAHYDROINDOLE-2-YL)METHYLENE]-2-INDOLINONE AND 3-[(CYCLOPENTANO-b-PYRROL-2-YL) METHYLENE]-2-INDOLINONE COMPOUNDS" by McMahon et al.; Ser. No. 60/031,588, filed Dec. 5, 1996, entitled "5-SUBSTITUTED INDOLINONE COMPOUNDS AS MODULATORS OF PROTEIN KINASE ACTIVITY" by McMahon et al.; Ser. No. 60/045,714, filed May 5, 1997, entitled "5-SUBSTITUTED INDOLINONE COMPOUNDS AS MODULATORS OF PROTEIN KINASE ACTIVITY" by McMahon et al.; Ser. No. 60/032,547, filed Dec. 5, 1996, entitled "SUBSTITUTED 3-[(TETRAHYDROINDOLE-2-YL)METHYLENE]-2-INDOLINONE AND 3-[(CYCLOPENTANO-b-PYRROL-2-YL) METHYLENE]-2-INDOLINONE COMPOUNDS" by McMahon et al.; Ser. No. 60/046,843, filed May 5, 1997, entitled "HYDROSOLUBLE INDOLINE TYROSINE KINASE INHIBITORS" by McMahon et al.; Ser. No. 60/031,585, filed Dec. 5, 1996, entitled "SUBSTITUTED 3-[(INDOLE-3-YL)METHYLENE]-2-INDOLINONE COMPOUNDS" by McMahon et al.; Ser. No. 60/031,565, filed May 5, 1997, entitled "SUBSTITUTED 3-[(INDOLE-3-YL)METHYLENE]-2-INDOLINONE COMPOUNDS" by McMahon et al. and this application also relates to U.S. patent application Ser. No. 08/702,232, filed Aug. 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang et al. which is a continuation-in-part application of U.S. patent applications Ser. No. 08/655,225, filed Jun. 5, 1996, now U.S. Pat. No. 5,834,504, entitled "3-(2'Halobenzylidenyl)-2-Indoline Compounds for the Treatment of Disease" by Tang et al.; Ser. No. 08/655,226, filed Jun. 5, 1996, now U.S. Pat. No. 5,886,020, entitled "3-(4'-Dimethylaminobenzylidenyl)-2-Indolinone and Analogues Thereof for the Treatment of Disease" by Tang et al.; Ser. No. 08/655,223, filed Jun. 5, 1996, now U.S. Pat. No. 5,792,783, entitled "3-Heteroaryl-2-Indolinone Compounds for the Treatment of Disease" by Tang et al.; Ser. No. 08/655,224, filed Jun. 5, 1996, now U.S. Pat. No. 5,883,116, entitled "3-(2'-Alkoxybenzylidenyl)-2-Indolinone and Analogues Thereof for the Treatment of Disease" by Tang et al.; and, Ser. No. 08/659,191, filed Jun. 5, 1996, now U.S. Pat. No. 5,883,113, entitled "3-(4'Bromobenzylindenyl)-2-Indolinone and Analogues Thereof for the Treatment of Disease" by Tang et al., all of which are continuations-in-part of U.S. patent application Ser. No. 08/485,323, filed Jun. 7, 1995, now U.S. Pat. No. 5,880,141 entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang et al. all of which are incorporated herein by reference in their entirety, including any drawings.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
RE36256 |
Spada et al. |
Jul 1999 |
|
4002749 |
Rovnyak |
Jan 1977 |
|
4053613 |
Rovnyak et al. |
Oct 1997 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
1398224 |
Mar 1965 |
FRX |
9910325 |
Mar 1999 |
WOX |
Non-Patent Literature Citations (1)
Entry |
Beilstein Reg. No.: 252929 Beilstein, 1923. |